Skip to content

Peptides for Sleep, Recovery, and Energy

PeptidespeptideEarly stage

Availability Not yet prescribable · sold for research use only

What it is

This family bundles three distinct lanes under "recovery": DSIP, a sleep-signaling peptide studied decades ago in chronic insomnia; MOTS-c, a mitochondrial-derived peptide tied to exercise adaptation; and elamipretide (SS-31), studied in serious mitochondrial disease. They're grouped together commercially, but aren't the same biology.

Why people take it

People ask about these peptides because sleep, training rebound, and energy set the tone for whether a longevity plan is sustainable. They sleep enough hours and still wake unrefreshed, take longer to bounce back from training, or feel depleted for days after travel.

How it's delivered

DSIP and MOTS-c are self-administered injections on a clinic-prescribed schedule. Elamipretide sits apart. Its only FDA approval, an accelerated approval in September 2025, covers a once-daily injection to improve muscle strength in people with Barth syndrome, a rare mitochondrial disease, who weigh at least 30 kg. Its dosing data come from trials in diagnosed disease, not from wellness clinics.

Where the evidence stands

DSIP's human evidence is limited to small, older studies in chronic insomnia, below the bar of modern sleep-medicine trials. MOTS-c carries strong biological interest as an exercise-responsive peptide, but most of its longevity-relevant evidence is still early or preclinical. Elamipretide has real trial data in primary mitochondrial myopathy for exercise tolerance and fatigue, evidence that belongs to that diagnosed population, not a casual energy claim.

Estimated cost

  • No verified reference price for DSIP or MOTS-c; neither is an approved product
  • Elamipretide's approved form is a rare-disease prescription, priced in a different bracket from wellness peptides
  • Not covered by insurance for wellness use

Who offers it

We don't list providers for these peptides. Elamipretide's approved form is a specialty prescription for Barth syndrome; DSIP and MOTS-c have no approved product.

Go deeper

The full guide, Peptides for Sleep, Recovery, and Energy, separates the sleep, exercise-mitochondrial, and clinical-disease lanes claim by claim. DSIP, MOTS-c, and elamipretide have their own entries in the peptide database.

Longevity.io is for educational purposes only and is not medical advice. Whether a recovery peptide belongs in your plan is a conversation for a clinician who knows your situation. Confirm eligibility, product source, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint